NASDAQ: KRYSKrystal Biotech Inc Stock
$164.10+0.32 (+0.2%)
Updated May 17, 2024
KRYS Price
$164.10
Fair Value Price
$26.81
Market Cap
$4.69B
52 Week Low
$93.95
52 Week High
$189.97
P/E
82.88x
P/B
5.86x
P/S
52.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$95.95M
Earnings
$57.16M
Gross Margin
94.3%
Operating Margin
61.62%
Profit Margin
59.6%
Debt to Equity
0.07
Operating Cash Flow
-$47M
Beta
1.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KRYS Overview
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KRYS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRYS ($164.10) is overvalued by 512.02% relative to our estimate of its Fair Value price of $26.81 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KRYS ($164.10) is not significantly undervalued (512.02%) relative to our estimate of its Fair Value price of $26.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRYS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRYS due diligence checks available for Premium users.
Be the first to know about important KRYS news, forecast changes, insider trades & much more!
KRYS News
Valuation
KRYS fair value
Fair Value of KRYS stock based on Discounted Cash Flow (DCF)
Price
$164.10
Fair Value
$26.81
Overvalued by
512.02%
KRYS ($164.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRYS ($164.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRYS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRYS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
82.88x
Industry
8.47x
Market
30.97x
KRYS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KRYS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
KRYS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.86x
Industry
6.01x
KRYS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRYS's financial health
Profit margin
Revenue
$45.3M
Net Income
$932.0k
Profit Margin
2.1%
KRYS's Earnings (EBIT) of $59.13M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$853.3M
Liabilities
$54.1M
Debt to equity
0.07
KRYS's short-term assets ($602.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRYS's short-term assets ($602.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRYS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KRYS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.9M
Investing
-$26.0M
Financing
$10.6M
KRYS's operating cash flow (-$46.76M)... subscribe to Premium to read more.
Debt Coverage Financials
KRYS vs Biotech Stocks
Krystal Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.